The purpose of the current study was to profile 24 inflammatory and immune-related plasma cytokines at baseline in immunotherapy-naïve NSCLC patients receiving anti-PD1 treatment and to evaluate those with potential as predictive and prognostic biomarkers that correlate to treatment response and progression-free survival (PFS). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.